We thus speculate once more that targeting endocytosis by p38 inhibition would reduce Rab5-mediated EGFR endocytosis and increase glioma cell resistance to gefitinib as has been found in the case of cisplatin treatment of U87 cells [60]. Here, RAB5A is linked to glioma.